Ovulation Induction for the Woman with Hypogonadotropic Hypogonadism

2020 ◽  
pp. 115-122
Author(s):  
Sezcan Mumusoglu ◽  
Pinar Tokdemir Calis ◽  
Gurkan Bozdag
Keyword(s):  
Ovulation Induction ◽  
Hypogonadotropic Hypogonadism

Infertility Treatment: Ovulation Induction and Insemination

2018 ◽  
Author(s):  
Quinton Katler ◽  
Jessica R Zolton ◽  
Alan H. DeCherney
Keyword(s):  
Ovulation Induction ◽  
Polycystic Ovarian Syndrome ◽  
Intrauterine Insemination ◽  
Semen Analysis ◽  
Clomiphene Citrate ◽  
Hypogonadotropic Hypogonadism ◽  
Unexplained Infertility ◽  
Male Factor ◽  
Ovarian Syndrome

For the majority of infertility patients, ovulation induction is the initial therapy. Treatment is individualized for a couple based on ovarian reserve testing, semen analysis, and the presence of anatomic pathology. Candidates for ovulation induction include those who are anovulatory and couples with unexplained infertility. The majority of patients diagnosed with anovulation have polycystic ovarian syndrome. Treatment options include clomiphene citrate and letrozole. For patients with hypogonadotropic hypogonadism, treatment involves injections with gonadotropins. Treatment is typically combined with intrauterine insemination to maximize pregnancy rates, especially in patients with male factor infertility or unexplained infertility. A stepwise approach is necessary, as patients who are unsuccessful with less invasive and costly treatments may eventually require in vitro fertilization. This review contains 7 figures, 3 tables and 57 references Key Words: clomiphene citrate, gonadotropins, infertility, intrauterine insemination, letrozole, ovulation induction, polycystic ovarian syndrome, unexplained infertility

scholarly journals Fertility management in Kallmann syndrome: a step towards optimization

2017 ◽  
Vol 6 (6) ◽  
pp. 2648
Author(s):  
Shikha Bathwal ◽  
Sunita Sharma ◽  
Nupur Agarwal ◽  
Baidyanath Chakravarty
Keyword(s):  
Hormone Therapy ◽  
Embryo Transfer ◽  
Ovulation Induction ◽  
Genetic Disorder ◽  
Hypogonadotropic Hypogonadism ◽  
Case Series ◽  
Kallmann Syndrome ◽  
Human Menopausal Gonadotropin ◽  
Fresh Embryo Transfer ◽  
The Third

Kallmann syndrome (KS) is a genetic disorder with an incidence of one per 50,000 women. It is associated with hypogonadotropic hypogonadism and anosmia/hyposmia. An important aspect of managing KS is to achieve successful pregnancy. We hereby present a case series of three patients with KS who successfully conceived with human menopausal gonadotropin (HMG) induction. One patient achieved pregnancy with ovulation induction, second with fresh embryo transfer and the third with frozen embryo transfer. Two of these three women delivered at term and both babies were doing well at one year of follow up. Both received cyclical hormone therapy (HT) since adolescence. The third patient received HT only for six months before starting ovulation induction. She conceived twice but miscarried at both occasions. At times, it may be challenging to attain fertility in Kallmann syndrome but with persistent efforts results are usually rewarding. It is important to diagnose KS and start hormone therapy at appropriate time so that satisfactory fertility outcome can be achieved.

Adjunctive medical treatments in follicular stimulation

1999 ◽  
Vol 7 (1) ◽  
pp. 27-39 ◽  
Author(s):  
Bryan D Cowan
Keyword(s):  
World Health Organization ◽  
Ovulation Induction ◽  
Hypogonadotropic Hypogonadism ◽  
World Health ◽  
Correct Classification ◽  
Polycystic Ovarian Disease ◽  
Medical Treatments ◽  
Follicular Stimulation ◽  
Health Organization ◽  
Common Intervention

Approximately 25% to 35% of couples that seek infertility services suffer from defects in ovulation.This diagnosis represents the single leading cause of infertility disorders, and makes medical ovulation induction the most common intervention for the treatment of infertility. There are two classes of correctable ovulation defects, and correct classification is correlated with treatment and prognosis. World Health Organization (WHO) I patients have ovulation defects associated with low estrogen and low gonadotropin levels and fail to exhibit withdrawal bleeding after progestin challenge. WHO II ovulation disorders occur in estrogenized/androgenized women who, in general, menstruate. Other names for these conditions include hypogonadotropic hypogonadism (WHO I) and polycystic ovarian disease (WHO II).

Sign in / Sign up

Export Citation Format

Share Document